These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 20887830)

  • 1. The association of ethnicity with antibody responses to pneumococcal vaccination among adults with HIV infection.
    Crum-Cianflone NF; Roediger M; Huppler Hullsiek K; Ganesan A; Landrum M; Weintrob A; Agan B; Medina S; Rahkola J; Hale B; Janoff EN;
    Vaccine; 2010 Nov; 28(48):7583-8. PubMed ID: 20887830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized clinical trial comparing revaccination with pneumococcal conjugate vaccine to polysaccharide vaccine among HIV-infected adults.
    Crum-Cianflone NF; Huppler Hullsiek K; Roediger M; Ganesan A; Patel S; Landrum ML; Weintrob A; Agan BK; Medina S; Rahkola J; Hale BR; Janoff EN;
    J Infect Dis; 2010 Oct; 202(7):1114-25. PubMed ID: 20795819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Race-related differences in functional antibody response to pneumococcal vaccination in HIV-infected individuals.
    Happe M; Samuvel DJ; Ohtola JA; Korte JE; Westerink MAJ
    Vaccine; 2019 Mar; 37(12):1622-1629. PubMed ID: 30797636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody persistence and immunologic memory after sequential pneumococcal conjugate and polysaccharide vaccination in HIV-infected children on highly active antiretroviral therapy.
    Abzug MJ; Song LY; Levin MJ; Nachman SA; Borkowsky W; Pelton SI;
    Vaccine; 2013 Oct; 31(42):4782-90. PubMed ID: 23954381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the safety and immunogenicity of a pneumococcal conjugate with a licensed polysaccharide vaccine in human immunodeficiency virus and non-human immunodeficiency virus-infected children.
    King JC; Vink PE; Farley JJ; Parks M; Smilie M; Madore D; Lichenstein R; Malinoski F
    Pediatr Infect Dis J; 1996 Mar; 15(3):192-6. PubMed ID: 8852905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serological response to 13-valent pneumococcal conjugate vaccine in children and adolescents with perinatally acquired HIV infection.
    Bamford A; Kelleher P; Lyall H; Haston M; Zancolli M; Goldblatt D; Kampmann B
    AIDS; 2014 Sep; 28(14):2033-43. PubMed ID: 25222526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serologic response to primary vaccination with 7-valent pneumococcal conjugate vaccine is better than with 23-valent pneumococcal polysaccharide vaccine in HIV-infected patients in the era of combination antiretroviral therapy.
    Lu CL; Hung CC; Chuang YC; Liu WC; Su CT; Su YC; Chang SF; Chang SY; Chang SC
    Hum Vaccin Immunother; 2013 Feb; 9(2):398-404. PubMed ID: 23291936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of previous vaccination with pneumococcal conjugate vaccine on pneumococcal polysaccharide vaccine antibody responses.
    Schaballie H; Wuyts G; Dillaerts D; Frans G; Moens L; Proesmans M; Vermeulen F; De Boeck K; Meyts I; Bossuyt X
    Clin Exp Immunol; 2016 Aug; 185(2):180-9. PubMed ID: 26939935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conjugate and polysaccharide pneumococcal vaccines do not improve initial response of the polysaccharide vaccine in HIV-infected adults.
    Peñaranda M; Payeras A; Cambra A; Mila J; Riera M;
    AIDS; 2010 May; 24(8):1226-8. PubMed ID: 20299956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of time since pneumococcal polysaccharide vaccine receipt and CD4 count with antibody response to the 13-valent pneumococcal conjugate vaccine in HIV-infected adults.
    Rossheim AE; Young AM; Siik J; Cunningham TD; Troy SB
    Hum Vaccin Immunother; 2016 Aug; 12(8):2117-2123. PubMed ID: 27172241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity following revaccination or sequential vaccination with 23-valent pneumococcal polysaccharide vaccine (PPSV23) in older adults and those at increased risk of pneumococcal disease: a review of the literature.
    Cripps AW; Folaranmi T; Johnson KD; Musey L; Niederman MS; Buchwald UK
    Expert Rev Vaccines; 2021 Mar; 20(3):257-267. PubMed ID: 33567914
    [No Abstract]   [Full Text] [Related]  

  • 12. No long-term evidence of hyporesponsiveness after use of pneumococcal conjugate vaccine in children previously immunized with pneumococcal polysaccharide vaccine.
    Licciardi PV; Toh ZQ; Clutterbuck EA; Balloch A; Marimla RA; Tikkanen L; Lamb KE; Bright KJ; Rabuatoka U; Tikoduadua L; Boelsen LK; Dunne EM; Satzke C; Cheung YB; Pollard AJ; Russell FM; Mulholland EK
    J Allergy Clin Immunol; 2016 Jun; 137(6):1772-1779.e11. PubMed ID: 26825000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Antibody Response Following a Booster With Either a 10- or 13-valent Pneumococcal Conjugate Vaccine in Toddlers Primed With a 13-valent Pneumococcal Conjugate Vaccine in Early Infancy.
    Trück J; Jawad S; Goldblatt D; Roalfe L; Snape MD; Voysey M; Pollard AJ
    Pediatr Infect Dis J; 2016 Jul; 35(7):787-93. PubMed ID: 27088583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The immunogenicity and safety of pneumococcal conjugate vaccine in human immunodeficiency virus-infected Thai children.
    Thanee C; Pancharoen C; Likitnukul S; Luangwedchakarn V; Umrod P; Phasomsap C; Apornpong T; Chuanchareon T; Butterworth O; Puthanakit T
    Vaccine; 2011 Aug; 29(35):5886-91. PubMed ID: 21729732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Streptococcus pneumoniae common protein antigen (CPA) antibodies and pneumococcal nasopharyngeal colonization in HIV-infected and HIV-uninfected African children.
    Ditse Z; Adrian PV; Kuwanda L; Madhi SA
    Vaccine; 2013 Sep; 31(40):4421-7. PubMed ID: 23845819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of serologic responses to vaccination with one dose or two doses of 7-valent pneumococcal conjugate vaccine in HIV-infected adult patients.
    Lu CL; Hung CC; Chuang YC; Liu WC; Su CT; Hsiao CF; Tseng YT; Su YC; Chang SF; Chang SY; Chang SC
    Vaccine; 2012 May; 30(24):3526-33. PubMed ID: 22484349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study.
    De Montalembert M; Abboud MR; Fiquet A; Inati A; Lebensburger JD; Kaddah N; Mokhtar G; Piga A; Halasa N; Inusa B; Rees DC; Heath PT; Telfer P; Driscoll C; Al Hajjar S; Tozzi A; Jiang Q; Emini EA; Gruber WC; Gurtman A; Scott DA
    Pediatr Blood Cancer; 2015 Aug; 62(8):1427-36. PubMed ID: 25810327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults.
    Musher DM; Manof SB; Liss C; McFetridge RD; Marchese RD; Bushnell B; Alvarez F; Painter C; Blum MD; Silber JL
    J Infect Dis; 2010 Feb; 201(4):516-24. PubMed ID: 20092407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants with human immunodeficiency virus type 1 infection.
    Nachman S; Kim S; King J; Abrams EJ; Margolis D; Petru A; Shearer W; Smith E; Moye J; Blanchard S; Hawkins E; Bouquin P; Vink P; Benson M; Estep S; Malinoski F;
    Pediatrics; 2003 Jul; 112(1 Pt 1):66-73. PubMed ID: 12837869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct Comparison of Immunogenicity Induced by 10- or 13-Valent Pneumococcal Conjugate Vaccine around the 11-Month Booster in Dutch Infants.
    Wijmenga-Monsuur AJ; van Westen E; Knol MJ; Jongerius RM; Zancolli M; Goldblatt D; van Gageldonk PG; Tcherniaeva I; Berbers GA; Rots NY
    PLoS One; 2015; 10(12):e0144739. PubMed ID: 26658902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.